Earnings call transcript: Cryoport Q1 2026 misses EPS but raises revenue guidance

Cryoport reported Q1 2026 revenue of $47.8 million, up 16% year over year and above the $44.87 million estimate, but EPS missed at -$0.25 versus -$0.22 expected. Management raised full-year 2026 revenue guidance to $192 million-$196 million and said it expects positive adjusted EBITDA in the second half, while shares rose 0.48% after hours to $10.40. The quarter was supported by 26% growth in commercial cell and gene therapy revenue, 18% growth in Life Sciences Services, and early traction from new offerings such as the Fusion 800 and IntegriCell.

Analysis

CYRX is starting to re-rate from a “show-me” story to a levered operating leverage story, but the market is still underappreciating how much of the upside is being driven by mix, not just volume. The important second-order effect is that commercial therapies are becoming more outpatient and geographically distributed, which expands the addressable logistics footprint per patient and should keep wallet share rising even if trial adds remain only modestly positive. That makes the business less dependent on headline trial counts and more exposed to the cadence of late-stage conversions, which is a higher-quality revenue driver over the next 6-18 months.

The stock’s biggest near-term setup is not the EPS miss; it is the combination of raised revenue guidance and a second-half EBITDA inflection with multiple facility ramps queued up. That said, this is still a “guidance quality” name: if those ramps slip even one quarter, the market will punish the multiple because the current move is already pricing in a cleaner profitability path. The balance-sheet support limits downside, but beta and valuation leave little room for disappointment if biotech funding rolls over or if the ramp in new sites/product launches is slower than management implies.

The cleaner trade is to own the operating leverage and avoid paying full multiple for the optionality. The contrarian angle is that the market may be over-focusing on commercial therapy growth while underestimating how much of the margin story is actually driven by internal efficiency gains and product mix normalization; if those are real, CYRX can outperform even with only mid-teens top-line growth. The better risk/reward is to own it into proof points over the next 2 quarters, not to chase the post-print pop.

Key Decisions for Investors

• Long CYRX on a 1-2 quarter horizon into the next two earnings prints; target 15-25% upside if revenue guidance is validated and EBITDA turns positive in 2H, with a stop if growth decelerates or gross margin compresses unexpectedly.
• Use call spreads in CYRX rather than outright equity to express the second-half leverage story; favor 3-6 month tenor to capture facility-ramp and commercial-launch optionality while capping downside to premium paid.
• Pair long CYRX / short a more fully valued healthcare services peer with lower growth and weaker balance-sheet support; the trade works if investors continue rewarding near-term revenue acceleration over current profitability.
• Avoid chasing on strength unless the next quarter confirms that new facilities and IntegriCell are contributing sooner than expected; the stock is vulnerable to a sharp multiple reset if the ramp narrative slips by even one reporting cycle.